Henrik Schmidt

9PUBLICATIONS
30CO-AUTHORS
Predictive and prognostic markersMechanobiologyMedical mycologyHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 31, 2026
Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma.

|Oct 19, 2025
Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.

Yago Garitaonaindia, Shawez Khan, Rasmus Friis

|Apr 14, 2025
Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility.

Jonas K Oddershede, Ida K Meklenborg, Lars Bastholt

|Feb 10, 2025
Risk of and Mortality After Acute Kidney Injury Following Cancer Treatment: A Cohort Study.

Philip Vestergaard Munch, Mette Nørgaard, Simon Kok Jensen

|Jul 27, 2024
Efficacy of Ipilimumab and Nivolumab in Patients with Melanoma and Brain Metastases-A Danish Real-World Cohort.

Karoline Dreyer Kattenhøj, Christine Louise Møberg, Louise Mahncke Guldbrandt

|Nov 13, 2021
Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study.

Morten Fink, Anders Schwartz Vittrup, Lars Bastholt

Pageof 2

Frequent Collaborators

4 joint publications

Lars Bastholt

4 joint publications

Eva Ellebaek

4 joint publications

Inge Marie Svane

4 joint publications

Marco Donia